|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Anaplastic large cell lymphoma (ALCL) represents a group of malignant T-cell lymphoproliferations that share morphological and immunophenotypical features, namely strong CD30 expression and variable loss of T-cell markers, but differ in clinical presentation and prognosis.
|
29617304 |
2018 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Pediatric anaplastic large-cell lymphoma (ALCL), which is characterized by strong expression of CD30, is usually responsive to multidrug chemotherapy.
|
31274669 |
2019 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.
|
11090048 |
2000 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299.
|
11313991 |
2001 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD30, however, is not a specific marker of anaplastic large cell lymphoma and has been found to be expressed in reactive as well as neoplastic populations as a probable activation marker.
|
11473453 |
2001 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD30 mAbs have been shown to be effective in in vitro and in vivo models of hematologic malignancies such as anaplastic large cell lymphoma, yet these mAb have not been efficacious in HD models.
|
12097283 |
2002 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD30-induced up-regulation of the inhibitor of apoptosis genes cIAP1 and cIAP2 in anaplastic large cell lymphoma cells.
|
15050749 |
2004 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD30 staining is observed in most cases, but is weaker and less homogeneous than in classic Hodgkin's lymphoma or anaplastic large cell lymphoma.
|
15202521 |
2003 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells.
|
17261581 |
2007 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD30, which is positive for anaplastic large cell lymphoma (Ki-1 lymphoma), was not expressed.
|
2004329 |
1991 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD30 is highly expressed on Hodgkins lymphoma and anaplastic large cell lymphoma, making it an attractive target for therapy.
|
23968853 |
2013 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD30 was assessed frequently but not uniformly in cases that were not anaplastic large cell lymphoma.
|
28209473 |
2017 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD30 aptamer-functionalized PEG-PLGA nanoparticles for the superior delivery of doxorubicin to anaplastic large cell lymphoma cells.
|
31002934 |
2019 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology.
|
9808552 |
1998 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A CD30-positive T cell line established from an aggressive anaplastic large cell lymphoma, originally diagnosed as Hodgkin's disease.
|
8035614 |
1994 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ALK(-) CD30(+) anaplastic large cell lymphoma is a type of non-Hodgkin lymphoma showing poor prognosis, and seldom co-occurs with sarcoidosis.
|
30909793 |
2019 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As expected, strong and membranous CD30 staining was seen in anaplastic large cell lymphoma, classical Hodgkin lymphoma, and embryonal carcinoma while variable staining was seen in diffuse large B cell lymphoma.
|
28521633 |
2017 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
c-Kit receptor (CD117) is expressed by erythroid, megakaryocytic, and myeloid precursors and mature mast cells and has been reported to be expressed in CD30+ lymphomas such as Hodgkin's disease and anaplastic large-cell lymphoma.
|
15105813 |
2004 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CCR3 was expressed in 73% of cases of CD30+ lymphoproliferative disorders such as lymphomatoid papulosis and anaplastic large cell lymphoma.
|
31045236 |
2019 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD30-positive primary cutaneous T-cell lymphoma (CTCL) includes mycosis fungoides, anaplastic large-cell lymphoma and lymphomatoid papulosis type A. Brentuximab vedotin (BV) consists of an antibody targeting CD30 with a protease-cleavable linker to vedotin.
|
28805086 |
2017 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Concentrations of interleukin-9, interleukin-10, interleukin-17a, hepatocyte growth factor, soluble interleukin-2 receptor, and soluble CD30 were significantly higher in initial sera of patients than in the sera of subjects from both control groups, indicating an anaplastic large cell lymphoma-type cytokine signature.
|
29242300 |
2018 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Current pathologic criteria cannot reliably distinguish cutaneous anaplastic large cell lymphoma from other CD30-positive T-cell lymphoproliferative disorders (lymphomatoid papulosis, systemic anaplastic large cell lymphoma with skin involvement, and transformed mycosis fungoides).
|
21169992 |
2011 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells.
|
11110706 |
2000 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Ets-1 activates overexpression of JunB and CD30 in Hodgkin's lymphoma and anaplastic large-cell lymphoma.
|
22107829 |
2012 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
High-CD30-expressing NHL patients (n=33) were enrolled except anaplastic large cell lymphoma.
|
31476851 |
2019 |